Cephalon Announces Strong Third Quarter Financi...(Other current assets ...)

Total current assets 1,365,996 1,108,804

PROPERTY AND EQUIPMENT, net 481,508 453,010

GOODWILL 476,605 467,167

INTANGIBLE ASSETS, net 839,255 793,037

DEFERRED TAX ASSETS, net 103,284 118,192

OTHER ASSETS 132,056 105,287

$3,398,704 $3,045,497

CURRENT LIABILITIES:

Current portion of long-term debt $1,237,285 $1,023,312

Accounts payable 74,528 90,586

Accrued expenses 685,864 263,478

Total current liabilities 1,997,677 1,377,376

LONG-TERM DEBT 4,373 224,992

DEFERRED TAX LIABILITIES, net 66,864 72,491

OTHER LIABILITIES 103,982 61,178

Total liabilities 2,172,896 1,736,037

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 693 678

Additional paid-in capital 1,899,761 1,780,749

Treasury stock, at cost (151,196) (151,068)

Accumulated deficit (668,310) (425,256)

Accumulated other comprehensive income 144,860 104,357

Total stockholders' equity 1,225,808 1,309,460

$3,398,704 $3,045,497

Certain reclassifications of prior year amounts have been made to conform to the current year presentation. The NUVIGIL(R) (armodafinil) [C-IV] i
'/>"/>